ArticleNucleic acids research2024
ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support.
Article in Nucleic acids research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 468 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
468 citing papers in PubMed.
- Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.Gut microbes · 2026Article
- Effects of lawsone and lawsone methyl ether on cyclooxygenase activity, redox balance, and organ-specific toxicity: An integrated computational and experimental study.Toxicology reports · 2026Article
- Breaking through the radiation dilemma: development and clinical translation of anti-radiation drugs.Pharmaceutical science advances · 2026Review
- Article
- Design, synthesis, and preliminary anticancer evaluation of diphenylpropan-1-one derivatives:RSC advances · 2026Article
- Design, microwave-assisted domino synthesis, and biological evaluation of novel naphtho[2,3-RSC advances · 2026Article
- Structure-based discovery of acridone alkaloids as disruptors of the HEG1-KRIT1 protein-protein interaction in cerebral cavernous malformation signaling.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Article
- Pharmacophore-guided identification and dynamic characterization of potential binders of the sporulation histidine kinase KinA in Bacillus subtilis.Archives of microbiology · 2026Article
- Cryptotanshinone and 15,16-dihydrotanshinone I fromRSC advances · 2026Article
- Peptidomics-guided 3D structural-mechanistic investigation of bovine colostrum peptides reveals multi-targetedFood chemistry: X · 2026Article
- Targeting a Leukemia-Relevant Protein-Protein Interface: N-Aryl Anthranilic Acids as Disruptors of the c-Myb-CBP/p300 KIX Interaction.Chemical biology & drug design · 2026Article
- An Integrated in Silico, in Vitro, and in Vivo Assessment of the Antioxidant and Neuroprotective Profile of Selenocyanate Compounds.Biological trace element research · 2026Article
- Target discovery and drug design in the era of artificial intelligence.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026Review
- AI-driven discovery of natural product-derived FAK1 inhibitors for idiopathic pulmonary fibrosis.Molecular diversity · 2026Article
- New 1,3-Oxazole and 1,2,4-Oxadiazole Derivatives as Novel Agents Against Human Rhinovirus and Cytomegalovirus.ChemMedChem · 2026Article
- Formalizing method choice: a data-driven selection of mechanistic models for predicting human heart drug partitioning.Journal of pharmacokinetics and pharmacodynamics · 2026Article
- Larvicidal Activity, GC-MS Profiling and Multitarget Molecular Docking of Essential Oils fromMolecules (Basel, Switzerland) · 2026Article
- Integration of network pharmacology, structure-based pharmacophore modeling, DFT, molecular docking, and molecular dynamics simulations to identify multi-target small molecule inhibitors against Alzheimer's disease.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Penetrating potential evaluation of cyclotriphosphazenes target blood-brain barrier via computational toxicology methods.iScience · 2026Article
- Article
408 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
ADMETlab 3.0 is the second updated version of the web server that provides a comprehensive and efficient platform for evaluating ADMET-related parameters as well as physicochemical properties and medicinal chemistry characteristics involved in the drug discovery process. This new release addresses the limitations of the previous version and offers broader coverage, improved performance, API functionality, and decision support. For supporting data and endpoints, this version includes 119 features, an increase of 31 compared to the previous version. The updated number of entries is 1.5 times larger than the previous version with over 400 000 entries. ADMETlab 3.0 incorporates a multi-task DMPNN architecture coupled with molecular descriptors, a method that not only guaranteed calculation speed for each endpoint simultaneously, but also achieved a superior performance in terms of accuracy and robustness. In addition, an API has been introduced to meet the growing demand for programmatic access to large amounts of data in ADMETlab 3.0. Moreover, this version includes uncertainty estimates in the prediction results, aiding in the confident selection of candidate compounds for further studies and experiments. ADMETlab 3.0 is publicly for access without the need for registration at: https://admetlab3.scbdd.com.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.